Drug Trial Radar · NCT04871282
A Study of AL102 in Patients With Progressing Desmoid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
198
Actual
Start
Sep 1, 2021
Primary completion
Dec 3, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Immunome, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Conditions
- Desmoid
- Desmoid Tumor
Interventions
AL102Drug
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
PlaceboOther
Placebo to match AL102
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability - Adverse EventsTime frame: Approximately 1.5 years
- Part B: Progression free survival (PFS)Time frame: Approximately 2 years
Locations
53 sites in 11 countries. Site status is shown where the registry gives one.
Mayo Clinic
Pheonix, Arizona
City of Hope
Duarte, California
Sarcoma Oncology Research Center
Santa Monica, California
University of California at Los Angeles Hematology/Oncology
Santa Monica, California
Stanford University Medical Center
Stanford, California
Mayo Clinic
Jacksonville, Florida
NorthShore University Health System
Evanston, Illinois
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Jefferson City Medical Group
Jefferson City, Missouri
Washington University
St Louis, Missouri
Columbia University Irving Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Cleveland Clinic
Cleveland, Ohio
Ohio State University Wexner Medical Center
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Jefferson University Hospital
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania
UTSW Simmons Cancer Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Adelaide Cancer Centre
Kurralta Park, South Australia, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Universitair Ziekenhuis
Ghent, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Helios Klinikum Berlin-Buch
Berlin, Germany
Mannheim university medical center
Mannheim, Germany
Oncology Institute Barzilai Medical Center
Ashkelon, Israel
Rambam MC
Haifa, Israel
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
IRCCS Fondazione Istituto Nazionale dei Tumori
Milan, Italy
Campus Bio-Medico University Hospital
Rome, Italy
The Netherlands Cancer Institute
Amsterdam, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.